The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
30-Jun-25
Pending
~$450 million
Target:
Environmental technology business of Dürr AG
Acquiror:
Stellex Capital Management LLC
Advising Dürr AG, one of the world's leading mechanical and plant engineering firms, on the sale of its environmental technology business to Stellex Capital Management LLC for an enterprise value of ~$450 million
13-Feb-25
$890 million
Target:
Renewi plc
Acquiror:
Consortium controlled by Macquarie Asset Management and BCI
Advising Renewi plc, a leading European waste-to-product company, on its £707 million recommended cash offer for its entire issued share capital from a consortium controlled by Macquarie Asset Management and British Columbia Infrastructure Management Corporation (BCI)
11-Feb-25
$320 million (AUD value)
Target:
Pacific Smiles Group
Acquiror:
Genesis Capital
Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover
10-Jan-25
Undisclosed
Target:
Ranger Design
Acquiror:
Clarience Technologies
Advised Ranger Design on its sale to Clarience Technologies, a portfolio company of Genstar Capital
24-Dec-24
Undisclosed
Target:
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Acquiror:
Neuraxpharm Group
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
08-Oct-24
Undisclosed
Target:
Danfoss Fire Safety A/S
Acquiror:
Siemens AG
Advising Danfoss A/S, one of the largest industrial groups in Denmark, on the sale of Danfoss Fire Safety A/S, a leading provider of certified fixed firefighting systems, to Siemens AG through its Smart Infrastructure segment
01-Oct-24
Undisclosed
Target:
Summit Electric Supply Co., Inc.
Acquiror:
Sonepar
Advised Summit Electric Supply Co., Inc, a founder and family-owned electrical distributor with operations across Arizona, Louisiana, New Mexico and Texas, on its sale to Sonepar USA Holdings, Inc., an independent, family-owned company with global market leadership in the B2B distribution of electrical products, solutions and related services
09-Sep-24
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
Henkel Corporation
Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company
13-Jun-24
Pending
$89 million
Target:
Voith HySTech GmbH
Acquiror:
Weifu High Technology Group
Advising Voith GmbH & Co. KGaA (“Voith”), a global diversified industrial technology company, on the sale of a 40% stake in Voith HySTech GmbH, Voith’s hydrogen storage system technology for heavy duty trucks and other applications, to Weifu High-Technology Group Co., Ltd. (SHE:200581), a listed China-based automotive supplier.
20-Feb-24
Pending
$185 million
Target:
myHomecare Group
Acquiror:
Australian Unity
Advising Australian Unity on its acquisition of myHomecare Group
11-Jan-24
Undisclosed
Target:
ElectraMeccanica
Acquiror:
Xos
Advising ElectraMeccanica on its all-stock merger with Xos, a leading manufacturer of battery electric commercial vehicles
08-Aug-23
Pending
Undisclosed
Target:
Farmalider Group
Acquiror:
MCH
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
13-Jul-23
$224 million
Target:
Distribuidora Internacional Carmen SAU
Acquiror:
Diploma PLC
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
01-Jun-23
$90.4 million
Target:
PCAS Canada Inc.
Acquiror:
DIC Corporation
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
27-Apr-23
$403 million
Target:
Distrelec BV
Acquiror:
RS Group plc
Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
05-Apr-23
Pending
$185 million
Target:
Calibre Group’s QuadR Business
Acquiror:
WSP Global Inc.
Advising Calibre Group, an Australian diversified engineering group, on the sale of its Calibre QuadR business to WSP Global Inc., a leading global engineering and professional services firm
29-Mar-23
Undisclosed
Target:
Scandinavian Enviro Systems AB
Acquiror:
Antin Infrastructure Partners
Advising Enviro on the creation of the world’s first large-scale tire recycling group in a JV with Antin Infrastructure Partners, supported by Michelin
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
09-Jan-23
Undisclosed
Target:
Schurter
Acquiror:
Capvis
Advising Capvis, a leading European mid-market investor, on the acquisition of Schurter, a global provider of components for circuit protection, connectors, switches and EMC products
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
23-Dec-22
Pending
Undisclosed
Target:
Exyte Management GmbH
Acquiror:
BDT Capital Partners LLC
Advising Stumpf Capital and Georg Stumpf on the sale of a minority interest in its wholly-owned company, Exyte, a global leader in the design, engineering and delivery of high-tech facilities, to funds affiliated with BDT Capital Partners
30-Nov-22
Pending
Undisclosed
Target:
Calibre Group’s Built Environment Business
Acquiror:
Egis S.A.
Advised Calibre Group, a leading Australian provider of sustainable engineering solutions, on the sale of its Built Environment business to Egis S.A., a French headquartered global consulting and engineering services firm owned by Tikehau Capital and Caisse des Dépôts
28-Nov-22
Pending
$650 million
Target:
Brambles (CHEP China)
Acquiror:
Loscam Greater China
Adviser to Brambles on the merger of its China business (CHEP China) with Loscam Greater China